查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401922

2030 年肺癌篩檢市場預測：按癌症類型、診斷類型、年齡層、最終用戶和地區進行的全球分析

Lung Cancer Screening Market Forecasts to 2030 - Global Analysis By Cancer Type, By Diagnosis Type, By Age Group, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球肺癌篩檢市場規模為 34 億美元，預計在預測期內複合年成長率為 10.1%，到 2030 年將達到 68 億美元。

肺癌篩檢涉及透過低劑量電腦斷層掃描 (LDCT) 掃描早期發現肺癌的診斷測試。供高風險族群使用，例如重度吸菸者。早期發現可以及時介入並改善治療結果。

據美國臨床腫瘤學會稱，肺癌是女性第二大常見癌症，預計到 2020 年將影響超過 235,000 名美國成年人。

患者對預防性醫療保健的需求不斷成長

隨著人們對早期檢測益處的認知不斷提高，患者擴大尋求預防措施，包括定期篩檢，以便在早期和可治療階段發現潛在的健康風險，例如肺癌。在教育和意識提升宣傳活動的推動下，主動健康管理的典範轉移與對預防性醫療保健的日益重視同時發生。隨著個人健康成為優先事項並選擇預防性醫療保健措施，對方便和全面的肺癌篩檢服務的需求將會增加，從而推動篩檢計畫的擴展和涵蓋常規醫療保健。

誤報風險

儘管篩檢計畫旨在及早發現潛在病例，但它們存在固有的誤報風險，這可能導致不必要的焦慮、後續觀察和侵入性干預。誤報可能是由於良性疾病或非癌性異常被檢測為潛在癌性而導致的，使患者的經歷複雜化並可能導致情緒困擾。除了給個人帶來情緒負擔外，誤報還可能導致額外的醫療費用以及用於後續檢測和不必要治療的資源佔用。

政府措施和資金

政府機構的支持性政策和財政支持可以提高篩檢計畫的可近性和可負擔性，並提高普及。隨著各國政府認知到早期癌症檢測的社會和經濟效益，他們正在加強投資力度，以提高肺癌篩檢的認知和實施。資金支持可以促進研究、技術進步和篩選基礎設施的建立。公共衛生機構、醫療保健提供者和政策制定者之間的合作努力將有助於制定有效的篩檢計劃，並向更廣泛的人群提供預防措施。

對輻射暴露的擔憂

篩檢，尤其是電腦斷層掃描（CT）檢查，在提供有價值的診斷資訊的同時，也引發了人們對輻射潛在健康風險的擔憂。電離輻射與罹患癌症的風險增加有關，因此頻繁體檢帶來的累積暴露是一個挑戰。重要的是要考慮早期癌症檢測的好處與輻射暴露的潛在危害之間的平衡。為了解決這些問題，人們正在努力盡量減少輻射劑量，包括使用低劑量 CT 掃描。然而，風險繼續阻礙人們參與篩檢計劃，並阻礙肺癌篩檢的廣泛普及。

COVID-19 的影響：

COVID-19 的疫情對市場產生了重大影響。醫療保健服務的中斷、資源的重新分配以及對病毒傳播的擔憂導致了常規檢查的減少。篩檢和診斷的延誤可能會延遲肺癌的檢測並影響治療結果。此外，對 COVID-19 的關注轉移了預防性醫療保健工作的注意力和資源。隨著衛生系統適應大流行的挑戰，需要製定策略來重新啟動並優先考慮肺癌篩檢工作，並確保持續提供及時有效的預防性衛生服務。

預計 X 光部門在預測期內將是最大的

在預測期內，X光領域的市場規模預計將擴大，並提供具有成本效益且廣泛使用的診斷工具。儘管不如電腦斷層掃描 (CT) 掃描靈敏，但 X 光在初步篩檢中發揮重要作用，可以幫助檢測肺部異常。攜帶式胸部 X 光檢查通常用於檢測肺癌的早期跡象，特別是在高風險族群中。 X光的易於引入有助於其廣泛普及，並促進常規篩檢和早期療育，從而提高肺癌篩檢計劃的整體有效性。

預計醫院業在預測期內複合年成長率最高。

預計醫院產業在預測期內將出現良好的成長。醫院配備電腦斷層掃描、X光等先進影像技術，有助於全面且準確地進行肺癌篩檢。包括肺科醫生和放射科醫生在內的多學科團隊確保採用整體方法進行診斷和後續護理。醫院在管理篩檢（從風險評估到結果解釋）方面發揮關鍵作用，並作為協調後續護理和介入措施的關鍵點。醫院作為集中的醫療機構，對肺癌篩檢舉措的可及性和有效性做出了重大貢獻。

佔有率最大的地區：

由於其強大的醫療基礎設施、不斷提高的預防醫學意識以及肺癌的高盛行率，預計北美地區將佔據最大的市場佔有率。既定的篩檢計劃和先進的醫療技術有助於早期發現。在政府的支持政策和醫療機構的積極努力下，篩檢服務的可近性正在不斷改善。該地區對早期診斷的重視，加上患者對預防措施不斷成長的需求，使北美處於肺癌篩檢舉措的前沿，推動創新並塑造全球肺癌篩檢市場的發展軌跡。

複合年成長率最高的地區：

預計亞太地區在預測期內將出現快速成長。該地區不斷成長的人口和日益增加的肺癌盛行率凸顯了對篩檢服務的需求。政府的措施和先進醫療技術的引進正在促進市場的成長。隨著中國和印度等國家的醫療保健系統優先考慮早期檢測，亞太地區肺癌篩檢市場預計將反映出積極主動的方法，以解決該地區日益成長的肺癌負擔。我們正在見證顯著的開拓。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球肺癌篩檢市場：依癌症類型分類

  • 非小細胞肺癌（NSCLC）
  • 小細胞肺癌
  • 其他

第6章全球肺癌篩檢市場：依診斷類型

  • 低劑量電腦斷層掃描 (LDCT)
  • X光
  • 其他

第7章全球肺癌篩檢市場：依年齡層

  • 少於 50
  • 50歲以上

第8章全球肺癌篩檢市場：依最終用戶分類

  • 醫院
  • 診斷中心
  • 其他最終用戶

第9章全球肺癌篩檢市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Siemens Healthineers AG
  • Canon Medical Systems Corporation
  • Koninklijke Philips NV
  • Medtronic
  • Nuance Communications, Inc.
  • PenRad Technologies, Inc.
  • Volpara Solutions Limited.
Product Code: SMRC24442

According to Stratistics MRC, the Global Lung Cancer Screening Market is accounted for $3.4 billion in 2023 and is expected to reach $6.8 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Lung cancer screening involves diagnostic tests to detect lung cancer in its early stages, typically through low-dose computed tomography (LDCT) scans. It is used for individuals at high risk, such as heavy smokers. Early detection allows for timely intervention, improving treatment outcomes.

According to the American Society of Clinical Oncology (2020), lung cancer is the second most common cancer in women and men is estimated to affect over 235,000 adults in the U.S in the year 2020.

Market Dynamics:

Driver:

Rising patient demand for preventive healthcare

With a growing awareness of the benefits of early detection, patients are actively seeking preventive measures, including routine screenings, to detect potential health risks such as lung cancer at an early and more treatable stage. The paradigm shift towards proactive health management, fueled by education and awareness campaigns, aligns with the rising emphasis on preventive care. As individuals prioritize their well-being and opt for preventive healthcare measures, the demand for accessible and comprehensive lung cancer screening services rises, driving the expansion and integration of screening programs into routine healthcare practices.

Restraint:

Risk of false positives

While screening programs aim to detect potential cases early, the inherent risk of false positives can lead to unnecessary anxiety, follow-up procedures, and invasive interventions. False positives can result from benign conditions or non-cancerous anomalies being detected as potentially cancerous, complicating patient experiences and potentially causing psychological distress. Beyond the emotional toll on individuals, false positives can lead to additional healthcare costs and resource utilization for follow-up tests and unnecessary treatments.

Opportunity:

Government initiatives and funding

Supportive policies and financial backing from governmental bodies enhance the accessibility and affordability of screening programs, encouraging widespread adoption. As governments recognize the societal and economic benefits of early cancer detection, they are increasingly investing in initiatives that promote lung cancer screening awareness and implementation. Funding can facilitate research, technological advancements, and the establishment of screening infrastructure. Collaborative efforts between public health agencies, healthcare providers, and policymakers contribute to the development of effective screening programs, making preventive measures accessible to a broader population.

Threat:

Radiation exposure concerns

While screening, particularly through computed tomography (CT) scans, provides valuable diagnostic information, it raises apprehensions about potential radiation-induced health risks. The cumulative exposure from frequent screenings poses a challenge, as ionizing radiation is associated with an increased risk of cancer development. Balancing the benefits of early cancer detection with the potential harm from radiation exposure is a critical consideration. Efforts to minimize radiation doses, such as the use of low-dose CT scans, are underway to address these concerns. However, the perceived risk may still deter individuals from participating in screening programs, hindering the broader adoption of lung cancer screenings.

COVID-19 Impact:

The COVID-19 pandemic has impacted the market profoundly. Disruptions in healthcare services, reallocation of resources, and concerns about virus transmission have led to a decline in routine screenings. Delays in screening and diagnosis may result in the identification of lung cancer at later stages, affecting treatment outcomes. Additionally, the focus on COVID-19 response has redirected attention and resources away from preventive healthcare initiatives. As healthcare systems adapt to pandemic challenges, there is a need for strategies to resume and prioritize lung cancer screening efforts, ensuring the continued provision of timely and effective preventive healthcare services.

The x-ray segment is expected to be the largest during the forecast period

Over the projection period, it is predicted that the x-ray segment will experience a larger market size, providing a cost-effective and widely accessible diagnostic tool. While not as sensitive as computed tomography (CT) scans, X-rays play a crucial role in initial screenings, aiding in the detection of lung abnormalities. Portable chest X-rays are commonly used to identify early signs of lung cancer, particularly in high-risk populations. The ease of X-ray implementation contributes to its widespread adoption, facilitating routine screenings and early interventions, thus enhancing the overall effectiveness of lung cancer screening programs.

The hospitals segment is expected to have the highest CAGR during the forecast period

During the forecast period, it is expected that the hospitals segment will experience lucrative growth. Equipped with advanced imaging technologies such as CT scans and X-rays, hospitals facilitate comprehensive and accurate lung cancer screenings. Their multidisciplinary teams, including pulmonologists and radiologists, ensure a holistic approach to diagnosis and subsequent care. Hospitals play a crucial role in managing screenings, from risk assessment to result interpretation, and serve as key points for coordinating follow-up care and interventions. As centralized healthcare institutions, hospitals contribute significantly to the accessibility and effectiveness of lung cancer screening initiatives.

Region with largest share:

The North America region is expected to witness largest market share, driven by a robust healthcare infrastructure, increasing awareness of preventive healthcare, and a high prevalence of lung cancer. Well-established screening programs and advanced medical technologies contribute to early detection efforts. Supportive government policies and the proactive approach of healthcare organizations enhance accessibility to screening services. The region's emphasis on early diagnosis, coupled with a rising patient demand for preventive measures, positions North America at the forefront of lung cancer screening initiatives, fostering innovation and shaping the trajectory of the global lung cancer screening market.

Region with highest CAGR:

During the forecast period, a rapid growth rate is anticipated in the Asia-Pacific region. The region's expanding population, coupled with a growing prevalence of lung cancer, underscores the demand for screening services. Government initiatives, coupled with the adoption of advanced medical technologies, contribute to the market's growth. As healthcare systems in countries like China and India prioritize early detection, the lung cancer screening market in Asia Pacific is witnessing significant development, reflecting a proactive approach to address the increasing burden of lung cancer in the region.

Key players in the market:

Some of the key players in Lung Cancer Screening market include FUJIFILM Holdings Corporation, GE Healthcare, Siemens Healthineers AG, Canon Medical Systems Corporation, Koninklijke Philips N.V., Medtronic, Nuance Communications, Inc., PenRad Technologies, Inc. and Volpara Solutions Limited.

Key Developments:

In August 2022, PenRad, a company that develops software to increase efficiency for breast imaging and lung screening, was acquired by Intelerad, a major international provider of enterprise medical imaging solutions. The purchase broadens Intelerad's product lines for lung analytics and mammography, enabling radiologists, technicians, and other healthcare workers to work more efficiently and fulfill increased demand for cancer screening while enhancing patient care.

In April 2023, Centers for Medicare & Medicaid Services (CMS) released a national coverage determination (NCD) that broadens coverage for lung cancer screening with Low Dose Computed Tomography (LDCT), to enhance health outcomes for those who have lung cancer,. In the U.S., lung cancer is one of the most prevalent malignancies and main reason for cancer-related mortality in both men and women.

Cancer Types Covered:

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer
  • Other Cancer Types

Diagnosis Types Covered:

  • Low-dose computed tomography (LDCT)
  • X-ray
  • Other Diagnosis Types

Age Groups Covered:

  • Below 50
  • 50 and older

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Lung Cancer Screening Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Non-small Cell Lung Cancer (NSCLC)
  • 5.3 Small Cell Lung Cancer
  • 5.4 Other Cancer Types

6 Global Lung Cancer Screening Market, By Diagnosis Type

  • 6.1 Introduction
  • 6.2 Low-dose computed tomography (LDCT)
  • 6.3 X-ray
  • 6.4 Other Diagnosis Types

7 Global Lung Cancer Screening Market, By Age Group

  • 7.1 Introduction
  • 7.2 Below 50
  • 7.3 50 and older

8 Global Lung Cancer Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Diagnostic Centers
  • 8.4 Other End Users

9 Global Lung Cancer Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 FUJIFILM Holdings Corporation
  • 11.2 GE Healthcare
  • 11.3 Siemens Healthineers AG
  • 11.4 Canon Medical Systems Corporation
  • 11.5 Koninklijke Philips N.V.
  • 11.6 Medtronic
  • 11.7 Nuance Communications, Inc.
  • 11.8 PenRad Technologies, Inc.
  • 11.9 Volpara Solutions Limited.

List of Tables

  • Table 1 Global Lung Cancer Screening Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 4 Global Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 5 Global Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 6 Global Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 7 Global Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 8 Global Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 9 Global Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 10 Global Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 11 Global Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 12 Global Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 13 Global Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 14 Global Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 15 Global Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 16 Global Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 17 North America Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 18 North America Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 19 North America Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 20 North America Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 21 North America Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 22 North America Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 23 North America Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 24 North America Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 25 North America Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 26 North America Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 27 North America Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 28 North America Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 29 North America Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 North America Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 North America Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 32 North America Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 33 Europe Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 34 Europe Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 35 Europe Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 36 Europe Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 37 Europe Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 38 Europe Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 39 Europe Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 40 Europe Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 41 Europe Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 42 Europe Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 43 Europe Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 44 Europe Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 45 Europe Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 46 Europe Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 47 Europe Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 48 Europe Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Asia Pacific Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Asia Pacific Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 51 Asia Pacific Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 52 Asia Pacific Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 53 Asia Pacific Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 54 Asia Pacific Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 55 Asia Pacific Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 56 Asia Pacific Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 57 Asia Pacific Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 58 Asia Pacific Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 59 Asia Pacific Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 60 Asia Pacific Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 61 Asia Pacific Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 62 Asia Pacific Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 63 Asia Pacific Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 64 Asia Pacific Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 65 South America Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 66 South America Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 67 South America Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 68 South America Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 69 South America Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 70 South America Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 71 South America Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 72 South America Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 73 South America Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 74 South America Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 75 South America Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 76 South America Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 77 South America Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 78 South America Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 79 South America Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 80 South America Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 Middle East & Africa Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 Middle East & Africa Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 83 Middle East & Africa Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 84 Middle East & Africa Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 85 Middle East & Africa Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 86 Middle East & Africa Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 87 Middle East & Africa Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 88 Middle East & Africa Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 89 Middle East & Africa Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 90 Middle East & Africa Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 91 Middle East & Africa Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 92 Middle East & Africa Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 93 Middle East & Africa Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 94 Middle East & Africa Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 95 Middle East & Africa Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 96 Middle East & Africa Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)